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Abstract
Background: Medical donation programs for drugs, other medical products, training and other supportive services
can improve access to essential medicines in low- and middle-income countries (LMICs) and provide emergency
and disaster relief. The scope and extent to which medical donation programs evaluate their impact on recipients
and health systems is not well documented.
Methods: We conducted a survey of the member organizations of the Partnership for Quality Medical Donations
(PQMD), a global alliance of non-profit and corporate organizations, to identify evaluations conducted in
conjunction with donation programs.
Results: Twenty-five out of the 36 PQMD organizations that were members at the time of the survey participated
in the study, for a response rate of 69 %. PQMD members provided information on 34 of their major medical
donation programs. Half of the donation programs reported conducting trainings as a part of their donation
program. Twenty-six (76 %) programs reported that they conduct routine monitoring of their donation programs.
Less than 30 % of donation programs were evaluated for their impact on health. Lack of technical staff and lack of
funding were reported as key barriers to conducting impact evaluations.
Conclusions: Member organizations of PQMD provide a broad range of medical donations, targeting a wide range
of public health issues and events. While some level of monitoring and evaluation was conducted in nearly 80 % of
the donation programs, a program’s impact was infrequently evaluated. Opportunities exist to develop consistent
metrics for medical donation programs, develop a common framework for impact evaluations, and advocate for
data collection and analysis plans that collect meaningful metrics.
Keywords: Medical Donations, Low- and Middle-Income Countries, Neglected Tropical Diseases, Monitoring,
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Background
Global access to quality medicines and other medical
products is fundamental to maintaining and improving
the health of people. Maintaining a reliable supply chain
of essential medicines and other medical products can
save lives, reduce morbidity, and improve quality of life.
Unfortunately, poor availability of medicines and other
medical products in many low- and middle-income coun-
tries (LMICs) where health systems, including supply
chains, are commonly suboptimal. Numerous studies have
described a lack of availability of essential medicines in
LMICs [1–5]. Moreover, poor quality medicines are a
global health problem, particularly in LMICs, resulting in
the potential for treatment failure, development of anti-
microbial resistance, and serious adverse drug reactions,
increasing healthcare costs and undermining the public’s
confidence in healthcare systems [6, 7].
The situation of poor access to medicines and other
medical products in LMICs is further compounded
when those countries are struck by natural disasters,
such as typhoons, hurricanes, tsunamis or earthquakes,
which put an even greater strain on their weak health
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systems. Among the top 10 countries in terms of disas-
ter mortality in 2014, seven countries are classified as
low income or lower-middle income countries [8]. In
response to these needs and concerns, nongovernmental
organizations (NGOs) and pharmaceutical and medical
supply manufacturers are involved in performing various
aspects of donations, including delivery and/or distribu-
tion of medical products and devices, and in-country
training and coordination activities [9, 10].
Donations of medicines and other medical products
are a key component of medical relief efforts, and repre-
sent a global response to countries and regions affected
by human and natural disasters [11]. Previously, there
was a widespread belief that any medicine is better than
none. However, reports of many unannounced, inappro-
priate, and unused donations to Bosnia-Herzegovina and
Croatia during war lead the World Health Organization
(WHO) to issue guidelines for international drug dona-
tions in 1996 [12–16]. The WHO guidelines were subse-
quently updated in 1999 and 2010, including adding a
section on monitoring and evaluation of drug donation
programs that focuses on evaluating the appropriateness
of medicine donations [12]. This section notes the import-
ance of “assessments of the administrative process used by
the donor agency, the adequacy of selection and forecast-
ing, appropriateness of the medicines, timeliness of deliv-
ery and changes in treatment guidelines.” The guidelines
also recommended using cost-benefit analysis to help
determine the donation’s “usefulness” to the donor and
the recipient.
However, a search of peer-reviewed literature yielded
few studies that evaluated the impact of medical dona-
tions. In a review of Medline (1946-May 2015) and
EMBASE (1996-May 2015), the authors found only five
impact evaluations of specific donations, all focusing on
large donation programs [17–21]. One of the best known
examples is the Mectizan® Donation Program by Merck
for treatment of river blindness and lymphatic filariasis
[22, 23]. There are also a few reports of the effects of drug
donation programs in the form of monographs [24, 25].
Additionally, there are a few published economic evalua-
tions of medical donation programs [26–29]. Given the
size and scale of global donation programs, there is a need
for more impact assessments and greater consistency and
transparency in reporting performance metrics.
The Partnership for Quality Medical Donations (PQMD)
is a global alliance of non-governmental organizations and
leading pharmaceutical companies, seeking to enhance
access to healthcare in underserved communities and
areas affected by disaster. Data collected from PQMD in
2015–16 estimated that over $3 billion in medical dona-
tions were provided as part of regular donation programs,
as well as donations in response to the earthquake in
Nepal, and the outbreaks of Ebola, and Zika [30]. PQMD
has published guidelines for medical donation programs,
which include the need for monitoring and evaluation of
donations to measure the effects, both long- and short-
term, and to learn from successes and challenges [31].
Given the lack of published data on the impact of global
medical donations, the goal of our study was to under-
stand the scope of medical donation programs and assess
how monitoring and evaluation and impact evaluations
have been carried out among PQMD members.
Methods
We conducted a survey of PQMD member organiza-
tions to better understand the scope of their donation
programs and the types of data currently being collected
as part of routine monitoring and evaluation activities,
as well as any impact evaluations that have been con-
ducted as part of a medical donation program. The
survey asked respondents to describe up to three major
donation programs offered by their organizations.
Questions about donation programs included when
each program was initiated, types of events targeted by
the donation, types of products donated and the geo-
graphical regions served. Respondents were then asked
to describe prior and ongoing monitoring and evalu-
ation activities, including any impact evaluations
conducted by the organizations.
To guide the design of the survey, we developed a con-
ceptual framework for assessing the impact of medical
donations (Fig. 1). Data collected as part of a medical do-
nation program can be classified based on whether they
describe the resources used, the outcome observed at the
program level, or the impact observed at the population
level. Examples of input indicators at the program level
include data on human and financial resources, quantity
of products distributed, and policies identified to initiate
the program. Examples of process indicators include
whether the donations were delivered on time, whether
other planned related activities were carried out as
intended, and how well planned activities were carried
out. Examples for output measures at the program level
include utilization, accessibility, and quality. Outcome, or
impact, is defined as changes in population health that
can be attributed to the program. Examples of impact
measures include mortality, morbidity, and disability-
adjusted life-years. Unlike other indicators, evaluation of
impact is typically based on models of cause and effect
and requires a counterfactual to control for factors other
than the intervention that might account for the observed
change in population health.
Results
Twenty-five out of 36 PQMD organizations that were
members at the time of the study completed the survey,
for a response rate of 69 %. Among the 25 organizations
Jenny et al. Globalization and Health  (2016) 12:69 Page 2 of 6
that completed the survey, 12 were corporations and 13
were non-governmental organizations. Twenty-one out of
25 organizations reported having been involved in provid-
ing medical donations for over 20 years. Similarly, 21 orga-
nizations reported having a person dedicated to managing
medical donations. Eighty-eight percent of organizations
reported having an internal policy on medical donations.
Thirty-six percent of organizations reported having a
publicly available external policy on medical donations.
Respondent organizations provided information on a
total of 34 donation programs. Characteristics of these
donation programs are summarized in Table 1. Thirty-
three out of 34 donation programs were ongoing as of
the date of the survey. Forty-four percent of donation
programs have been operating for over a decade, while
29 % were initiated within the past five years. These pro-
grams were reportedly described by respondents because
they meet a major unmet need, have the most units do-
nated, are of strategic importance to the organization,
are the longest or are most costly. The reported goals of
these donation programs included donating medicines,
equipment, and funding; providing direct care to pa-
tients; addressing rare diseases; educating healthcare
professionals, volunteers, technicians, and patients; and
managing supply chains. Sub-Saharan Africa and Latin
America were the two regions most frequently targeted
by the donation programs. Thirteen out of 34 donation
programs targeted less than or equal to five different
countries. Seven targeted over 50 countries. Recipient
country coordination of donations was usually through
local hospitals and medical professionals, host-nation
Ministry of Health, regional or country office of the
organization, and host-nation NGOs.
Donations consisted of a wide range of medical products
and services (Table 1). Medical devices, anti-infectives,
analgesics, and medical supplies were among the most fre-
quently donated products. The estimated fair market value
(FMV) for the donated products for these programs
ranged from under one million to over 50 million US
dollars (USD). Nine programs donated products that were
reportedly valued at more than 50 million USD. The most
common estimation method for the FMV was the whole-
sale acquisition cost (WAC), with 16 programs reporting
having used this estimation method. Some organizations
also reported using internal formulas or list prices to
calculate the FMVs for donated products.
Fig. 1 Framework for Measuring Impact of Medical Donations
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Seventeen out of 34 (50 %) donation programs re-
ported conducting training as a part of their donation
program (Table 2). Trainings were provided in the topic
areas of disease diagnosis and treatment, nursing skills,
maternal and neonatal care, pharmaceutical products
usage, mass drug administration, waste management,
Table 1 Donation program characteristics by whether an
impact evaluation was reported
Total
(n = 34)
Year program was initiated
2005 and before 15 (44 %)
2006–2010 7 (21 %)
2011–2015 10 (29 %)
Don’t know 2 (7 %)
Reasons considered a major donation program
Addresses a major unmet need 26 (76 %)
Has the most units donated 18 (53 %)
Of strategic importance to the organization 18 (53 %)
One of the longest 14 (41 %)
One of the most costly 8 (24 %)
Has the most employees work on it 7 (21 %)
Othera 5 (15 %)
Types of events targeted by donation
Ongoing unmet needs in low-resource settings 23 (68 %)
Strengthening or rebuilding healthcare infrastructures 14 (41 %)
Natural disaster 9 (26 %)
Epidemics 8 (24 %)
Complex emergencies, conflict, war 6 (18 %)
Displaced populations, refugee support 6 (18 %)
Famine, food insecurity 2 (7 %)
Otherb 7 (21 %)
Types of products donated
Medical devices, medical equipment 23 (68 %)
Anti-infectives 14 (41 %)
Medical supplies 13 (38 %)
Analgesics 11 (32 %)
Nutritional 10 (29 %)
Respiratory 9 (26 %)
Skin 9 (26 %)
Gastrointestinal 7 (21 %)
Vaccines 7 (21 %)
Oncology medications 6 (18 %)
Oral health 5 (15 %)
Diabetes medications 3 (9 %)
Vector control 2 (6 %)
Otherc 4 (12 %)
Estimated fair market value (FMV) of donationsd
≥$50,000,000 9 (26 %)
$25,000,000–$49,999,999 6 (18 %)
$5,000,000–$24,999,999 5 (15 %)
Table 1 Donation program characteristics by whether an
impact evaluation was reported (Continued)
$1,000,000–$4,999,999 7 (21 %)
<$1,000,000 3 (9 %)
Don’t know 4 (12 %)
aOther reasons that were mentioned in the responses included combining
equipment and clinical training; maintaining customer relations; strengthening
healthcare system; historical involvement with the disease; and involving a
reliable, capacity building partner
bOther types of events included continuing education; support to frontline
health workers; rare diseases; and breast cancer
cOther types of donated products included anesthetics; medicines for
cardiovascular diseases; medicines for mental illnesses; ophthalmic medicines;
and enzyme replacement therapies for rare diseases
dSome organizations used internal formulas or list prices to calculate the FMVs
for donated products
Table 2 Training, monitoring, and impact evaluations
Frequency
(n = 34)
Training conducted as part of the donation program
Yes 17 (50 %)
Program monitoring conducted
Yes 26 (76 %)
Phase when monitoring plan was developed
Inception of the program 13 (38 %)
During the program 11 (32 %)
After products were donated or distributed 12 (35 %)
Impact evaluations conducted
Yes 10 (29 %)
Phase when impact evaluation was developed
Inception of the program 6 (18 %)
During the program 6 (18 %)
After products were donated or distributed 4 (12 %)
Cost of impact evaluation
≤$50,000 7 (21 %)
$50,001–$100,000 0
$100,001–$250,000 2 (6 %)
$250,001–$500,000 0
>$500,000 1 (3 %)
Reasons for not conducting impact evaluations
Lack of technical staff to conduct impact evaluation 9 (26 %)
Lack of funding 6 (18 %)
Lack of donor interest 2 (6 %)
Lack of CO or NGO interest 3 (9 %)
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healthcare facility management, supply chain manage-
ment, health worker safety, application for drug donations,
and program monitoring and evaluation. The format of
trainings usually consisted of classroom training, mentor-
ships, or virtual training. External groups involved in pro-
viding the training included donor partners, local and
international universities, US-based medical research
groups, host-nation ministries of health, international
organizations, and external NGOs.
Of the 34 donation programs, 10 (29 %) were reported
to have been evaluated for their impact Each of the orga-
nizations that reported conducting an impact evaluation
worked in the area of medication donation for more
than two decades and reported key staff were devoted to
managing medical donations. The longer an organization
was engaged in medical donation programs, the greater
likelihood that a rigorous evaluation was conducted, as
was having staff dedicated to the medical donations
program. Two key barriers to conducting impact evalua-
tions for medical donation programs reported by the
respondents were lack of technical staff and lack of
funding. Impact evaluations that met stakeholders’ needs
were often reported to be “very costly”, and some orga-
nizations indicated they could not afford such impact
evaluations. Seven out of the 10 impact evaluations in
this survey were reported to cost less than or equal to
50,000 USD. Impact evaluations were conducted by
internal evaluation departments, local and international
universities, recipient health facilities, and external NGOs.
Similar to monitoring plans, impact evaluations were
developed at various phases of the program.
Metrics chosen for impact evaluations depended on
the nature of the medical donations. Some examples of
reported metrics were quantity of donations; number of
patients receiving and benefiting from the treatment;
improvement in knowledge and skills; usefulness of train-
ing; deficits in budgets of the ministry of health; and
participating health facilities.
Findings from impact evaluations were reported to have
been disseminated to key stakeholders and the general
public through periodic reports, end-user reports, periodic
meetings, presentations at forums and conferences, web-
sites and other social media, and scientific publications.
Findings were reportedly used to improve the donation
program, set the stage for establishing future partnerships,
demonstrate continual improvement of internal process
and commitment to patients and healthcare, and improve
donor-recipient relationships and encourage increased
quantity and improved quality medical donations.
Discussion
Findings from this survey demonstrate that responding
organizations provide a broad range of medical donations,
targeting a wide range of public health issues and events.
Nearly 80 % of the donation programs in this study re-
ported having conducted some level of monitoring and
evaluation. However, the types of metrics used in reported
evaluations varied greatly. Units of donation and number
of patients receiving the donation were often reported to
be tracked in an ongoing fashion since they are generally
more readily available. However, a program’s impact at the
population level was infrequently evaluated. When a pro-
gram was evaluated, metrics chosen depended on the
nature of the medical donations, and some epidemio-
logical and economic outcomes were reported to have
been used by a few member organizations.
Most of the impact evaluations reported in this study
were relatively small in scale, costing under $50,000. Some
organizations indicated that with limited resources, they
could only afford small-scale evaluations of the donation
programs, although these evaluations may not fully meet
stakeholders’ needs. Lack of technical staff and lack of
funding were cited as key barriers to conducting a rigor-
ous impact evaluation, despite of a considerable amount
of interest in it among PQMD member organizations.
While the survey provides a baseline assessment of
past and current evaluations, there were some limita-
tions to this survey. The donation programs described in
this study are not representative of the full range of do-
nation programs among the organizations surveyed, nor
do they represent the totality of medical donation pro-
grams in general, and thus should not be generalized as
such. The survey was limited to asking about major
donation programs, and the judgment of whether a do-
nation program can be considered a major one was left
to the respondents. While the purpose of this survey
was to provide insights into the breadth and depth of
medical donation programs and evaluations by PQMD
members, the survey was not tailored to a specific type
of donation or organization. As a result, some respon-
dents may have found some questions not applicable to
their organizations or their donation programs. Finally,
while a 69 % response rate is generally recognized as
acceptable, a higher response rate would have provided
more confidence in the generalizability of our results
and reduced the likelihood of non-response bias.
Conclusions
An evaluation should not be an end in itself but rather a
means to an end. Factors in deciding when to do an
impact evaluation should include the need to demon-
strate the impact to key stakeholders, the availability of
resources to collect and analyze necessary data, and the
stage of the program. All types of programs can benefit
from sound monitoring and evaluation, and this in-
cludes developing a well thought out analysis plan.
Findings from well-conducted impact evaluations can
help with making decisions about programs, practices,
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and policies, and would benefit both donors and recipients
of medical donation programs.
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